Authors
Latest:
Dr. Garcia-Carbonero on Quality of Life Impact of FOLFIRI Plus Ramucirumab in mCRCRocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study. The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.
Latest:
Dr. Amaria on Dabrafenib Plus Trametinib in MelanomaRodabe N. Amaria, MD, assistant professor Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of a recent trial testing neoadjuvant and adjuvant dabrafenib plus trametinib versus standard of care in high-risk resectable BRAF-mutant melanoma.
Latest:
Dr. Amaria on Genetically Modified TILs in MelanomaRodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.
Latest:
Dr. Pommier Discusses Challenges Associated With the Treatment of Carcinoid SyndromeRodney F. Pommier, MD, professor of surgery, director, Neuroendocrine Tumor Program, Oregon Health & Science University, discusses challenges associated with the treatment of carcinoid syndrome.
Latest:
Dr. Goncalves on the ESR1 Mutation in Breast CancerRodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, describes research involving the ESR1 gene mutation in breast cancer.
Latest:
Novel Molecular Targets for Drug Development in Non-GIST SarcomasThe characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases.
Latest:
Dr. Verhaak Discusses Genomic Characterization of Diffuse Lower Grade GliomasRoeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.
Latest:
Dr. Stupp on Final Results for TTFields Added to Chemo in GlioblastomaRoger Stupp, MD, professor, Neurological Surgery, and associate director, Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields (TTFields) added to standard chemotherapy in newly diagnosed glioblastoma during the AACR Annual Meeting.
Latest:
Dr. Lilenbaum on the Rise of Immunotherapy in NSCLCRogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.
Latest:
Dr. Lilenbaum on the Clinical Implications of the FDA Approval of Lurbinectedin in SCLCRogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.
Latest:
Dr. Vivaldi on the Gaucher Disease TransformationDr. Rogerio Vivaldi the President of Genzyme Corporation on the Transformation of Gaucher Disease
Latest:
HIPEC for Ovarian Cancer: An Exciting Locoregional StrategyApproximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.
Latest:
Effective Management and Prevention of Neratinib-Induced DiarrheaSafety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.
Latest:
Dr. Stahel on Treatment Sequencing in Stage IV NSCLCRolf A. Stahel, MD, professor in the oncology clinic, University Hospital, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer.
Latest:
Dr. Perez-Soler on the Utility of Liquid Biopsy in Lung CancerRoman Perez-Soler, MD, discusses the utility of liquid biopsy in lung cancer.
Latest:
Dr. Ron Bose on HER2 Gene Mutations in Breast CancerRon Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.
Latest:
Dr. Natale on the Evolution of Immunotherapy in NSCLCRonald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.
Latest:
Dr. de Wit on the AEs With Cabazitaxel in the CARD Trial in mCRPCRonald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).
Latest:
Dr. Go on Treatment of Patients With Thrombotic MicroangiopathyRonald Go, MD, associate professor of Medicine, Mayo Clinic, discusses treatment for patients with thrombotic microangiopathy.
Latest:
Dr. Hoffman on the Design of an Ongoing Trial Testing PTG-300 in Polycythemia VeraRonald Hoffman, MD, discusses the design of an ongoing phase 2 trial evaluating the first-in-class synthetic hepcidin mimetic PTG-300 in patients with polycythemia vera.
Latest:
Dr. Natale on the Evolution of Immunotherapy in NSCLCRonald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.
Latest:
New Perioperative Strategies Emerge for High-Risk, Resectable RCCThe current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.
Latest:
Dr. Kelly on Trials Evaluating Frontline Immunotherapy Combinations in ESCCRonan J. Kelly, MD, MBA, discusses the variety of clinical trials investigating immunotherapy with or without chemotherapy in patients with esophageal squamous cell carcinoma.
Latest:
Bringing Epigenetic Therapies From Bench to BedsideEpigenetic therapy has emerged as a novel approach, not necessarily by killing cancer cells, but perhaps by altering the network of chemical changes that affect the DNA/chromatin within cancer cells.
Latest:
Dr. Swords on Anti-Tumor Effects of IMG-98 in AMLRonan T. Swords, MD, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acid–based therapies in acute myeloid leukemia.
Latest:
Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.
Latest:
Dr. McCulloch on the Likelihood of Relapse on a BTK Inhibitor in MCLRory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).
